To:

Head of Paediatric Medicines
European Medicines Agency

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): Adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid (ABBV-154)

Invented name: NA

Latest Decision number(s): 1) P/0454/2021

Corresponding PIP number(s): 1) EMEA-002927-PIP01-20

Date of initial marketing authorisation granted: Not Applicable - MAA not submitted

Date of authorisation of new indication, pharmaceutical form or route of administration: Not Applicable

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☐ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☐ other reason (please specify:)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

AbbVie made the decision to discontinue development of ABBV-154, effective April 27, 2023. ABBV-154 was being developed for Rheumatoid Arthritis (RA), Polymyalgia Rheumatica (PMR) and Crohn's disease (CD).

AbbVie voluntarily terminated all clinical development for ABBV-154, including the 3 ongoing Phase 2 clinical trials [M20-466 for Rheumatoid Arthritis (RA), M20-370 for Polymyalgia Rheumatica (PMR) and M20-371 for Crohn's disease (CD)], effective 27 April 2023. Based on interim data review of the Phase 2 RA, PMR, and CD studies, the benefit-risk profile did not sufficiently differentiate ABBV-154 from other currently available therapies. The 3 studies were not terminated due to safety reasons. AbbVie also received PIP product waiver (Decision No. P/0124/2022; PIP No. EMEA-002927-PIP02-21) for PMR in all subsets of the paediatric population, for all pharmaceutical forms and routes of administration on the grounds that the disease or condition does not occur in all subsets of the paeditaric population.

The development of ABBV-154 is not being discontinued due to safety reasons and there are no potential risks to the health of clinical trial subjects or other persons to disclose.

Please note that if the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies to the PIP in question:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Name and signature of the PIP contact point: signature on file

Date: 28.06.2023

Contact for inquiries from interested parties: AbbVie Ltd

Telephone: +44 (0) 1628 408 248

Email: paediatricteam@abbvie.com